Ubiquitin-conjugating enzyme E2 T (UBE2T) (UBE2T)

Ubiquitin-conjugating enzyme E2 T (UBE2T) is a critical E2 enzyme within the Fanconi anemia (FA) DNA repair pathway, where it facilitates the monoubiquitination of the FANCD2-FANCI complex (UniProt Q9NPD8). This enzymatic step is essential for the repair of DNA interstrand cross-links, thereby ensuring genomic stability during replication (NCBI Gene: 29089). UBE2T is frequently overexpressed in a wide range of malignancies, including breast, lung, and hepatocellular carcinomas, where it acts as an oncogene to promote cell proliferation, epithelial-mesenchymal transition, and resistance to DNA-damaging chemotherapy (PubMed: 30603351). Consequently, UBE2T mRNA has emerged as a significant therapeutic target, with strategies such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) being developed to downregulate its expression (PubMed: 32853215). Additionally, small molecule inhibitors are being explored to block the protein's catalytic activity and sensitize cancer cells to treatment. Beyond its role as a target, UBE2T mRNA levels serve as a valuable prognostic biomarker, correlating with poor clinical outcomes in cancer patients.

Other names

HSPC150PIG7Ubiquitin-protein ligase TFanconi anemia complementation group TFANCT

Targeted degradation of UBE2T mRNA via RNA interference or antisense mechanisms, or small molecule inhibition of the E2 enzyme's catalytic activity to disrupt the Fanconi anemia DNA repair pathway.